Outpatient Pharmacy Benefit
What is the Outpatient Pharmacy Benefit?
The outpatient pharmacy benefit includes a comprehensive list of prescription drugs, plus certain select OTC products. The outpatient pharmacy benefit also includes the Home Infusion Therapy (HIT) program that covers self-administered infusion therapy, including IV chemotherapy and IV antibiotics.
Preferred Drug List
The Preferred Drug List (PDL) is a list of drugs covered by Carolina Complete Health. Carolina Complete Health works with the State of North Carolina to ensure that medications used to treat a variety of conditions and diseases are covered. The Preferred Drug List includes drugs you receive at retail pharmacies. Carolina Complete Health adheres to the NC Medicaid Preferred Drug List.
Which drugs are covered?
The Preferred Drug List (PDL) allows NC Medicaid to obtain better prices for covered outpatient drugs through supplemental rebates. The PDL was authorized by the NC General Assembly Session Law 2009-451, Sections 10.66(a)-(d).
- Prescribers are encouraged to write prescriptions for “preferred” products.
- Prescribers may continue to write prescriptions for drugs not on the PDL.
- If a prescriber deems that the patient’s clinical status necessitates therapy with a non-preferred drug, the prescriber will be responsible for initiating a prior authorization request.
- Prior authorization requirements may be added to additional drugs in the future.
- Submit Proposed Clinical Policy Changes to the PDL
- Preferred Drug List Review Panel
- Preferred Drug List
How to obtain medication pre-authorization?
If a prescriber deems that the patient’s clinical status necessitates therapy with a non-preferred drug, the prescriber will be responsible for initiating a prior authorization request.
Prior Authorization Forms
- Anklosing Spondylitis (PDF)
- Behcet's Disease (Otezla) (PDF)
- Crohn's Disease (Adult) (PDF)
- Crohn's Disease (Pediatric) (PDF)
- Cryopyrin-Associated Periodic Syndromes including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) (Arcalyst and Ilaris) (PDF)
- Cytokine Release Syndrome (Actemra and Actemra SQ) (PDF)
- Deficiency of Interleukin-1 Receptor Antagonist (DIRA) (Arcalyst and Kineret) (PDF)
- Familial Mediterranean Fever (FMF) (PDF)
- Giant Cell Arteritis (Actemra and Actemra SQ) (PDF)
- Hidradenitis Suppurativa (Humira) (PDF)
- Neonatal Onset: Multi-System Infammatory Disease (Kineret) (PDF)
- Neuromyelitis Optica Spectrum Disorder (NMOSD) (Uplizna and Enspryng) (PDF)
- Non-Infectious Intermediate Posterior Panuveitis (PDF)
- Non-Radiographic Axial Spondyloarthritis (Cimzia, Cosentyx and Taltz) (PDF)
- Plaque Psoriasis (Adult) (PDF)
- Plaque Psoriasis (Pediatric) (PDF)
- Polyarticular Juvenile Idiopathic Arthritis (Enbrel, Humira, Actemra SQ, Actemra Infusion, Orencia Infusion and Orencia SQ) (PDF)
- Psoriatic Arthritis (PDF)
- Rheumatoid Arthritis (Enbrel, Humira, Actemra Infusion, Actemra SQ, Cimzia, Inflectra, Kevzara, Kineret, Olumiant, Orencia Infusion, Orencia SQ, Remicade, Renflexis, Rinvoq ER, Simponi, Simponi Aria, Xeljanz and Xeljanz XR (PDF)
- Still's Disease - Adult Onset (Ilaris) (PDF)
- Systemic Onset Juvenile Idiopathic Arthritis (For Actemra SQ, Actemra Infusion and Ilaris) (PDF)
- Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) (PDF)
- Ulcerative Colitis (Adult) (PDF)
- Ulcerative Colitis (Pediatric) (PDF)
- Dupixent - Asthma (PDF)
- Dupixent for Atopic Dermatitis (PDF)
- Dupixent for Eosinophilic Esophagitis (PDF)
- Dupixent for Nasal Polyps (PDF)
- Dupixent for Prurigo Nodularis (PDF)
- Monoclonal Adbry (PDF)
- Monoclonal Antibody Therapy - Nucala (PDF)
- Monoclonal Antibody Therapy - Xolair (PDF)
- Monoclonal Antibodies: Xolair Nasal Polyps (PDF)
- Monoclonal Tezspire (PDF)
- Standard Drug Request Form (PDF)
- Aduhelm Request Form (PDF)
- Adult Safety with Antipsychotic Prescribing (ASAP) Beneficiaries 18 Years of Age or Older (PDF)
- Amondys 45 (PDF)
- Antiparkinson's Agents: Gocovri and Osmolex (PDF)
- Antiparkinson's Agents: Inbrija and Ongentys (PDF)
- Antipsychotics - Keeping it Documented for Safety (A+KIDS) for Safety Beneficiaries 17 Years of Age and Younger (PDF)
- Botox/Dysport/Myyobloc (PDF)
- Camzyos (PDF)
- Cialis (PDF)
- Continuous Glucose Monitors (PDF)
- Crinone 8% Gel (PDF)
- Cystic Fibrosis Medications (PDF)
- Emend/Aprepitant (PDF)
- Emflaza (PDF)
- Entresto (PDF)
- Epidiolex (PDF)
- Epinephrine Pens (PDF)
- Evrysdi (PDF)
- Exondys 51 (PDF)
- Fasenra (PDF)
- Gattex (PDF)
- GLP-1 for Weight Management (PDF)
- GLP-1 Receptor Agonists (PDF)
- Growth Hormone - Adult 21 Years of Age and Older (PDF)
- Growth Hormone - Children Less than 21 Years of Age (PDF)
- Hereditary Angioedema (HAE)(PDF)
- Hetlioz and Hetlioz LQ (PDF)
- Hormonal Products for Beneficiaries under 18 years of age (PDF)
- Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) - (ILARIS) (PDF)
- Juxtapid or Kynamro (PDF)
- Topical Local Anesthetics (PDF)
- Leqembi (PDF)
- Lupus Medication - Benlysta (PDF)
- Lupus Medication - Lupkynis (PDF)
- Lupus Medication - Saphnelo (PDF)
- Migraine Calcitonin Agents: Aimovig/Ajovy/Emgality/Vyepti (PDF)
- Migraine Calcitonin Agents: Ubrelvy (PDF)
- Migraine Calcitonin Gene Related Therapy (PDF)
- Movement Disorders: Xenazine and Tetrabenazine (PDF)
- Neonatal Onset: Multi-System Inflammatory Disease - (Kineret) (PDF)
- Nexletol and Nexlizet (PDF)
- Non-Covered State Medicaid Plan Services Request Form for Recipients under 21 Years Old (PDF)
- Palivizumab (Synagis) (PDF)
- PCSK9 Inhibitors (PDF)
- Procrit/Epogen/Aranesp (PDF)
- Sedative Hypnotics (PDF)
- Selective Constipation Agents (Relistor) (PDF)
- Stromectol (Ivermectin) Tablets (PDF)
- Topical Antihistamines (PDF)
- Topical Anti-Inflamatory Medications (PDF)
- Triptans (PDF)
- Vivjoa (PDF)
- Vowst (PDF)
- Vusion (PDF)
- Zolgensma (PDF)
Three ways providers may submit Outpatient Pharmacy Requests:
- Cover My Meds Portal
- Fax completed Prior Authorization Forms to 1-833-404-2393
- Call the Prescriber Help Desk at 1-833-585-4309
Disclaimer: For durable medical equipment, medical services, procedures, and nursing visits (including home infusion nursing visits). Please refer to the Medicaid Pre-Auth Tool for more information.
Coverage Resources:
Please use the following resources for coverage details: